![](\"https:\/\/cannabiscultivatornews.com\/home\/wp-content\/uploads\/2022\/10\/MM_Bill_Tracker_V5_blank-21.jpg\"){kind=tracking}
<\/p>\n <\/p>\n
The Drug Enforcement Administration (DEA) wants to more than double the amount of marijuana that can be legally manufactured for research in 2023\u2014and it\u2019s also seeking to significantly increase the quota for the production of psychedelics like psilocyn, LSD and mescaline.<\/p>\n
In a notice set to be published in the Federal Register next week, DEA proposed growing about 6.7 million grams (or 14,770 pounds) of cannabis. The agency\u2019s final marijuana quota for 2022 was 3.2 million grams<\/a>, and it was two million grams for 2021<\/a>.<\/p>\n\n Growing that much cannabis may be easier since DEA finally authorized additional manufacturers<\/a> at the beginning of the year. Those approved cultivators are now able to apply for a contract to be federal marijuana suppliers<\/a> for study purposes under the National Institute on Drug Abuse (NIDA).<\/p>\n DEA has also been consistently increasing the production goals for psychedelics in recent years as more states and localities have enacted reform and interest in their therapeutic potential has boomed.<\/p>\n The proposed quota for psilocybin is the same in 2023 as it was this year, at 8,000 grams. But it\u2019s looking to double the manufacturing of the other key ingredient in so-called magic mushrooms, psilocyn, from 4,000 to 8,000 grams.<\/p>\n \u201cThere has been a significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes,\u201d the agency said. \u201cDEA has received and subsequently approved new registration applications for schedule I researchers and new applications for registration from manufacturers to grow, synthesize, extract, and prepare dosage forms containing specific schedule I hallucinogenic substances for clinical trial purposes.\u201d<\/p>\n For LSD, the agency\u2019s 2023 quota is 1,200 grams, almost triple the 500 gram production level for this year. Further, it wants 6,000 grams of 5-MeO-DMT, versus 2,550 in 2022.<\/p>\n DEA is also proposing to dramatically increase how much mescaline is produced, from 100 to 1,200 grams.<\/p>\n That psychedelic, which naturally occurs in peyote and other cacti, is sometimes excluded from decriminalization proposals out of concern about over-harvesting threatening supplies for indigenous communities that use it ritualistically. But it can also be produced synthetically.<\/p>\n \u201cThese proposed 2023 quotas reflect the quantities that DEA believes are necessary to meet the estimated medical, scientific, research, and industrial needs of the United States, including any increase in demand for certain controlled substances used to treat patients with COVID-19; lawful export requirements; and the establishment and maintenance of reserve stocks,\u201d DEA said.<\/p>\n Additionally, the agency upped the quota for \u201call other THC\u201d\u2014from 2,000 to 15,000 grams\u2014which may reflect the growing interest and marketing of intoxicating cannabinoids other than delta-9 THC, such as delta-8 and delta-10.<\/p>\n While those lesser-known cannabinoids aren\u2019t currently classified as controlled substances when derived from legal hemp, the agency said that it \u201csupports regulated research with schedule I controlled substances, as evidenced by increases proposed for 2023 as compared with aggregate production quotas for these substances in 2022.\u201d<\/p>\n Meanwhile, DEA has kept the quotas the same for 2023 for other psychedelics of interest, such as psilocybin (8,000 grams), MDMA (8,200 grams), DMT (3,00 grams), MDA (200 grams) and marijuana extract (one million grams).<\/p>\n
![\"\"](\"https:\/\/cannabiscultivatornews.com\/home\/wp-content\/uploads\/2022\/10\/MM_Bill_Tracker_V5_blank-20.jpg\"){kind=tracking}
<\/a>